|
|
|
|
|
|
|
|
|
|
RayBiotech, Inc. and Abeome Corporation Announce an Agreement Related to Novel Research Products for Ovarian Cancer - MarketWatch
NORCROSS, Ga., Nov. 1, 2012 /PRNewswire via COMTEX/ --
RayBiotech, Inc. and Abeome Corporation today announced that the
companies have entered into a collaboration whereby Abeome will provide
over 300 novel monoclonal antibodies recognizing human ovarian cancer
for use in the development of RayBiotech's antibody-related portfolio of
products. These antibodies recognize ovarian cancer but not normal
ovary tissue. Financial terms were not disclosed.
RayBiotech's President, Chief Operating Officer and Co-Founder, Rani
Huang stated, "Ovarian cancer is a devastating disease and most often
goes undetected until very late stages of progression. This alliance
with Abeome will enable RayBiotech to provide products and services for
the preclinical characterization of ovarian cancer-related biological
samples. We are delighted to have entered into this agreement with
another Georgia-based bioreagent company."....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.